We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Clovis Oncology Fined $20 Million for Misleading Efficacy Data
Clovis Oncology Fined $20 Million for Misleading Efficacy Data
The Securities and Exchange Commission (SEC) Tuesday levied a $20.8 million fine against biopharmaceutical company Clovis Oncology and two company executives for concealing the true efficacy rate of its lung cancer drug Roci (rociletinib).